Recently, Morgan Stanley Capital International (MSCI), a leading global index provider, released its latest annual ESG (Environmental, Social, and Governance) ratings. Fosun Pharma ascended to an 'AA' rating, highlighting its exceptional performance in sustainable development, reflecting its leadership position within the domestic pharmaceutical industry and underscoring its ongoing advancements in ESG governance and execution.

Hong Kong, July 23, 2025 — Amid Hong Kong’s accelerating embrace of the digital asset economy, Finloop Finance Technology Holding Limited (“Finloop”), a global one-stop Web5 wealth technology platform incubated by Fosun Wealth Holdings under Fosun, held the “Finloop · Chain to the Future 2025: Web3 Strategy Upgrade and RWA Platform Launch Summit” at Hong Kong Cyberport on July 23. Finloop officially announced its Web5 Strategy and unveiled its global leading one-stop RWA (Real World Assets) technology, issuance, and distribution platform—“FinRWA Platform (FRP)”—ushering in a new era of integration between traditional finance and digital assets.

2025 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer(IASLC)  will be held from September 6-9 in Barcelona, Spain. At the conference, Henlius will showcase 10 latest results from its innovative products on lung cancer, which includes 3 oral presentations and 2 poster tours, covering updated phase 1 clinical data for PD-L1 ADC HLX43, the results(first release) from ASTRUM-002, a phase 3 clinical trial of serplulimab (anti-PD-1 monoclonal antibody) in the first line treatment of advanced non-squamous non small cell lung cancer (NSCLC) as oral presentation, along with further research findings on serplulimab in lung cancer, making it the Chinese biopharmaceautical with most oral presentations.

On July 21, 2025, the Board of Directors of Club Med Holding is pleased to announce the appointment of Stéphane Maquaire as the President and Chief Executive Officer of Club Med Holding, effective immediately.

On 18 July 2025, – Standard & Poor’s (S&P), one of the world’s leading international credit rating agencies, initiated coverage and assigned Fidelidade – Companhia de Seguros, S.A. and its reinsurance company, Fidelidade RE – Companhia de Resseguros, S.A., long-term Issuer Credit Ratings (ICR) and Financial Strength Ratings (FSR) of ‘A’, with a stable outlook.

(July 9, 2025, Shanghai, China）— On 9 July, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; Stock Code: 600196.SH, 02196.HK), announced that its self-developed MEK1/2 selective inhibitor Fu Mai Ning (generic name: Luvometinib Tablets; the “Drug”) has entered Phase 3 clinical trial for the treatment of pediatric low-grade glioma (pLGG) in China (excluding Hong Kong SAR, Macau SAR and Taiwan region).

Recently, Henlius has achieved significant advancement in the global development of HLX43, its innovative programmed death-ligand 1 (PD-L1) targeting antibody-drug conjugate (ADC), which has already been approved by the China National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA), Australia Therapeutic Goods Administration (TGA) and Japan`s Pharmaceuticals and Medical Devices Agency (PMDA) to initiate phase 2 multi-regional clinical trial in patients with advanced non-small cell lung cancer (NSCLC). Additionally, the first patient dosing has been completed in China. To date, no PD-L1 targeting ADC has been approved for marketing globally. HLX43 is the first PD-L1 ADC progressed to phase 2 clinical trial development globally.

On 8 July 2025, the world’s leading index company, FTSE Russell, recently announced the latest Environmental, Social and Governance (ESG) rating results for Fosun International Limited (HKEX stock code: 00656) (“Fosun International”). In 2025, Fosun International’s FTSE Russell ESG rating was upgraded to 3.9, consistently outperforming the global industry average (2.6) and the national average (2.0), while maintaining its inclusion in the FTSE4Good Index Series for the fourth consecutive years.

The most authoritative corporate governance magazine in the Asia Pacific region, Corporate Governance Asia, has recently presented the 15th Asian Excellence Award. Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of Fosun International, were awarded Asia’s Best CEO by the magazine.